The variation generated by germline mutation is essential for evolution, but individuals pay a steep price in the form of Mendelian disease and genetic predisposition to complex disease. Indeed, the health of a species is determined ultimately by the rate of germline mutation. Analysis of the factor IX gene in patients with hemophilia B has provided insights into the human germline mutational process. Herein, seven topics will be reviewed with emphasis on recent advances: (i) proposed mechanisms of deletions, inversions, and insertions; (ii) discordant sex ratios of mutation and associated age effects; (iii) somatic mosaicism; (iv) founder effects; (v) mutation rates; (vi) the factor IX gene as a germline mutagen test; and (vii) cancer as a possible mechanism for maintaining a constant rate of germline mutation.
INTRODUCTION
The human factor IX gene has highly advantageous properties for the study of germline mutations (see Table 1 ). By careful attention to the possible biases [e.g., see (1) (2) (3) (4) (5) ] , it has been possible to deduce the underlying pattern of mutation at this locus. Recent observations in this system will be emphasized; more detail on earlier work may be found in previous reviews (3, 6, 7) . For overviews of human germline mutation, see Cooper and Krawczak (8) and the 'Mutation Update' section of the journal Human Mutation. An annual database of factor IX germline mutations currently lists 1380 point mutations, microdeletions and/or microinsertions (9) . The wealth of missense mutations can now be located within a recently available crystal structure (10) .
Since many independent point mutations are available, the factor IX gene has been utilized to develop and/or validate multiple methods of mutation detection (e.g., PASA, double PASA, and SNuPE) (11) (12) (13) or mutation screening (chemical cleavage, rSSCP, ddF, Bi-ddF, REF, and heteroduplex analysis) [(14-20) , respectively]. In addition, recent reviews document that study of the factor IX gene has provided insight into other fields: e.g., structure-function analyses (21) , genotype-to-phenotype analyses (22) , gene regulation (23) , molecular diagnosis/genetic counseling (24) , and gene therapy (25) (26) (27) .
I. MECHANISMS OF INSERTIONS AND DELETIONS: INTERACTING ALTERNATING PURINE-PYRIMIDINE HAIRPIN LOOPS AS A NOVEL MECHANISM FOR CONCERTED DELETIONS
Microinsertions/microdeletions (v20 bp) are more common than large deletions or insertions (see Table 4 in ref. 28,) . Microinsertions presumably derive from polymerase slippage events since a direct repeat is generated in nearly every reported factor IX microinsertion (Ketterling et al., in preparation) . In contrast, most factor IX microdeletions do not eliminate repeat units. Most of the reported microdeletions are unique, but hotspots have been detected at two sites (29) . These microdeletion hotspots generate perfect hairpin loops from imperfect, or quasipalindromic, sequences. Such quasipalindromic sequences were found previously to be hotspots of microdeletions in E. coli and yeast (30, 31) .
Genes with either highly homologous segments (e.g., steroid sulfatase and α-globin) or excessive gene length (e.g., dystrophin) are predisposed to large deletions (i.e., >20 bp) (32) (33) (34) . However, in the great majority of genes, large deletions generally account for only 5-10% of the observed mutations. In the factor IX gene, large deletions account for 6% of observed, independent mutations. Insertions and duplications are much rarer than large deletions (35) . Only one transposition of an Alu1 sequence and only one partial gene duplication have been described (36, 37) . While pure insertions are rare, deletions are often associated with insertions. Of the nine large deletions with junctions that have been defined in the 33 kb factor IX gene, five are associated with insertions (28) . The insertions can be inversions of segments within the deleted regions, orphan sequences (i.e., novel sequences of unknown origin), or both. Two factor IX deletions with inversions but no orphan sequences fit a proposed 'doubleloop model' (38) . In brief, a 'double-loop' structure forms when two short (5-7 bp) sets of complementary sequences anneal within single-stranded DNA, presumably during DNA replication or repair. Subsequent endonuclease cleavage, DNA repair, and mismatch correction delete segments in both loops and invert the loop connector. Since the sequence complementarity required for the double-loop mechanism is substantial, the likelihood is very small (p <10 -8 ) that the required sequences are present at the deletion-inversion junctions by random chance. Recently, other replication-based models for deletions with inversions have been proposed (39) . These models are distinct from recombination at highly homologous repeats, a mechanism responsible for the high frequency of inversions in severe hemophilia A (40, 41) .
Long segments of alternating purine and pyrimidine segments [RY(i)] in the factor IX gene occur in intron 1 and in the 3′ untranslated region (42, 43) . These RY(i) are 'cryptic' repeats because the simple nature of the repeat unit is only apparent when the sequences are categorized into purines and pyrimidines. These RY(i) are hotspots of microdeletions/microinsertions with mutation rates, such that race-specific alleles tend to occur (43, 44) . The eight different alleles found at the long cryptic repeat in intron 1 seem to result from a combination of polymerase slippage events and recombination (43) .
These cryptic RY(i) sequences may well predispose to large deletions (28) . Of the 17 defined factor IX deletion junctions reviewed, RY(i) were present at one or both of the junctions 18% of the time, although such segments constitute only 0.7% of the factor IX gene sequence. The mutation in one patient, HB128, is of particular interest. The patient initially was thought to have a 24.5 kb deletion without insertions, but subsequent analysis revealed a downstream 50 bp deletion at a distance of 2.3 kb (Fig.  1A) . Haplotype, sequence, and paternity analyses determined that these 'two' deletions occurred in the germline of the maternal grandfather (45) .
Long hairpin loops composed of the RY(i) in the factor IX gene are present at the flanking deletion junctions in HB128 (Fig. 1A) . Are seemingly simple deletions, in which one of the junctions occurs in a hairpin sequence, associated with a deletion in a neighboring hairpin region? Surprisingly, few deletion junctions have been sequenced in genes without known highly homologous repeats. The junction sequences for 18 large simple deletions (i.e., without insertions) from multiple genes were analyzed to identify potential nucleic acid secondary structures. A deletion junction with a large RY(i) hairpin was found in the type III procollagen gene from a patient with Ehlers-Danlos type 4 (46) (Fig. 1B) . Thus, another ostensibly simple deletion has a signature RY(i) hairpin. The presence of another RY(i) hairpin at one of these 18 deletion junctions is a highly nonrandom event, since only 0.1% of human genomic sequence contains RY(i), and the overwhelming majority of RY(i) are not self-complementary (42) . Unfortunately, neither intronic nor flanking intragenic sequence was available for the type III procollagen gene so neighboring RY(i) hairpins could not be identified to determine if a second deletion is present.
How might interactions between RY(i) initiate concerted deletions? In this regard, it is intriguing that stable four-stranded structures spontaneously result from the association of RY(i) sequences (47) . These structures can spontaneously form from duplex DNA in the absence of protein. Furthermore, gel-retardation assays demonstrate that the four-stranded structures can associate specifically with nuclear-high-mobility-group proteins 1 and 2. Perhaps illegitimate recombination at such structures initiates concerted deletions.
II. MALE:FEMALE SEX RATIOS OF MUTATION (SRM) AND MATERNAL AGE EFFECTS
In an analysis of 15 families from Sweden with sporadic hemophilia B in which the mother was either a carrier (n = 12) or a noncarrier (n = 3), an aggregate SRM of 11 was calculated (48, 49) . These non-Bayesian calculations did not take the pedigree structure of the ascertained families into account and assumed an equilibrium between selection and mutation. Other non-Bayesian analyses in which germline origins in mothers and grandmothers were pooled and compared to origins in grandfathers yielded aggregate SRM values of 2 (50, 51) . A Bayesian analysis of 29 factor IX origins, which considered pedigree structure, estimated an overall SRM for factor IX germline origins of 3.5 (95% confidence interval of 1.5-8.4) (4). Recently, this Bayesian analysis was extended to include a total of 59 defined origins of mutation. Based on these data, the SRMs were estimated for six types of mutation ( Table 2 ). The estimated aggregate SRM was 3.75, but the SRMs ranged from 6.65 and 6.10 for transitions at CpG and A:T→G:C transitions at non-CpG dinucleotides, respectively, to 0.57 and 0.42 for microinsertions/ microdeletions and deletions (>20 bp), respectively. Surprisingly, the two subtypes of non-CpG transitions possessed markedly different SRMs (6.10 for A:T→G:C vs. 0.80 for G:C→A:T). In contrast, inversion mutations in the X-linked factor VIII gene, which are presumptively due to homologous recombination, are almost exclusively paternal in origin (estimated SRM of 302) (52, 53) . Table 1 . Advantages of the Hemophilia B/factor IX model for studying human germline mutation
Hemophilia B
Common Mendelian disease for which care is centralized X-linked recessive disease of historically low reproductive fitness; i.e., most mutations have occurred within the past 150 years. The clinical diagnosis implies a mutation at the factor IX locus Independent mutations occur in 95 + % of all families with severe/moderate disease Almost all cases in the population are diagnosed A small reduction in enzymatic activity produces disease Epidemiological data is available on the incidence of de novo disease Fetal survival is uncompromised Little, if any, heterozygote advantage occurs in females Shimmin et al. (54) estimated the aggregate SRM during primate evolution by examining intronic regions from homologous zinc finger genes on both the X and Y chromosomes. Their data consisted of point mutation analyses and suggested an overall 'male-driven evolution' (estimated SRM = 6). A similar analysis in rodents suggests a SRM of only two (55, 56) .
Does parental age at conception affect the risk of mutation? Oocytes arrest in meiosis at five months gestation while spermatocytes undergo mitosis approximately every 14 days after puberty. By age 30, about 15-fold more divisions occur in the male germline than in the female germline (57) . If mutations occur during DNA replication, the male germline should have a much higher mutation rate than the female germline due to continual post-pubertal mitotic divisions. In addition, the likelihood of germline mutation should increase in older males (paternal age effect).
While studies of some Mendelian X-linked and autosomal dominant diseases generally found an advanced paternal age effect [reviewed in (57) ], studies of other diseases found only a mild or absent paternal age effect (58) (59) (60) (61) . In these studies, the causative mutation generally was not defined. In addition, the influence of imprinting on autosomal genes may play an important role and affect interpretation of the age analyses.
Studies of age effects on X-linked genes avoids the bias of imprinting. Mutation screening coupled with direct genomic sequencing facilitates the detection of germline origins. However, appropriate interpretation of the data depends critically on at least six ascertainment biases, i.e., the biases of: pedigree structure, family pursuit, generational proximity, gender-based inferences, mutation detection, and sex ratio [see (4); Ketterling et al., submitted] .
Paternal origins of mutation have been defined for 22 single-base substitutions and three deletions in the factor IX gene (Ketterling et al., submitted) . The average age percentiles for the 18 Caucasian paternal origins were not elevated for any mutation subtype or in total (51.4%) ( Fig. 2A) . In contrast, the age percentiles of the 23 Caucasian maternal origins were elevated for non-CpG transitions (68.7%) and transversions (78.5%) and in total (68%) (Fig. 2B) . The markedly unequal distribution seen for the maternal age percentiles was statistically significant (p = 0.03).
The absence of a paternal age effect suggests that errors during DNA replication do not play the dominant role in the generation of germline mutations. Perhaps certain types of mutations occur preferentially in the male germline because of less efficient DNA repair, higher levels of reactive cellular metabolites, or differences in DNA or chromatin structure. For at least one type of mutation with a high SRM, transitions at the dinucleotide CpG, the known mechanism of mutation strongly suggests that the SRM is due to profound deficiency in DNA methylation in oocytes (62) , rather than replication errors. Why is there an increased age effect in females? Does the cellular machinery become error prone after being in stationary phase for many years? The generality of the maternal age effect will need to be assessed as germline origins for point mutations accumulate in other Mendelian disorders.
III. MOSAICISM: A HIGH RATE OF G:C→A:T NON-CPG TRANSITIONS EARLY IN EMBRYOGENESIS
Mosaicism has been documented for chromosomal aberrations, mitochondrial mutations, triplet repeat diseases and a growing number of dominant and X-linked single gene disorders. Somatic mosaicism is sometimes responsible for mild phenotypic manifestations of a new mutation (63) and could allow the survival of a normally lethal phenotype as hypothesized for the McCune-Albright syndrome (64) . As a result of numerous cell divisions during life, each individual displays some degree of mosaicism, but most of these mutations are phenotypically silent [see calculations in (65) ]. The effect of a mutation that causes a loss of gene function depends on the stage of development at which it occurs: a mutation in an embryo might result in malformations (66) or inborn errors of metabolism. In an adult, mutations can cause malfunction (as in aging) or overgrowth (as in neoplasia) (63) . The phenotypic manifestation also depends on the tissues involved. An early mutation before lineage allocation results in both germline and somatic mosaicism. Isolated germline mosaicism arises from a mutation in a precursor cell committed to only germline development. Additionally, a mutant allele might survive only in certain tissues (i.e. germline) because it is lethal for other cell types. Detailed studies in Duchenne's muscular dystrophy (DMD) have illustrated the clinical importance of germline mosaicism in a human disease (67, 68) . Bakker et al. (67) found that six of 41 (15%) DMD families had detectable germline mosaicism while van Essen (68) found a recurrence risk of 20% for subsequent siblings due to maternal germline mosaicism. Other than the above studies on deletions, reports of germline or somatic mosaicism have historically been limited to single case reports.
Of the factor IX germline origins determined in 59 families by haplotype and sequence analyses, no examples were identified in which the mutant allele was transmitted to more than one of the children tested. However, in four origin individuals (Ketterling et al., submitted) , somatic mosaicism and, by implication, germline mosaicism occurred. In one additional family, a mosaic female with an approximately 50:50 ratio of wildtype:mutant signal in leukocytes had one carrier and four noncarrier daughters who inherited the haplotype associated with the mutation (69). Thus, in total, of the 45 origins which could be visualized directly by sequence analysis, five (11%) exhibited mosaicism due to a mutation within a few cell divisions after fertilization. Seventeen families were analyzed recently by methods which should detect mosaicism at frequencies of 1-0.01% (70) . Early embryogenesis may be a highly mutagenic period while later embryogenesis is less mutagenic, since no additional somatic mosaicism was identified in these families.
Four of these five mosaics had G:C→A:T non-CpG transitions (p = 0.01). Is this non-CpG transition subtype truly associated with somatic mosaicism? Is early embryogenesis a highly mutagenic period of development, particularly for G:C→A:T non-CpG transition mutations? While there are multiple examples of somatic mosaicism associated with germline deletions [e.g., (67, (71) (72) (73) ], only five other examples of somatic mosaicism associated with single-base germline substitutions were found in the literature (74) (75) (76) (77) (78) . It is intriguing that three of these five changes were G:C→A:T non-CpG transitions. Thus, seven of ten germline, single-base substitutions associated with somatic mosaicism were G:C→A:T non-CpG transitions.
IV. HEMOPHILIA B FOUNDER EFFECTS: A SMALL AMINO ACID TARGET FOR MILD DISEASE
Four founder effects are prevalent in U.S. Caucasian hemophiliacs (79-83). The founder mutations are responsible for about 30% of all disease cases (84/276 mutations in one study) (83) . The G60S and T296M mutations reproducibly cause clinically mild hemophilia, while the R248Q and I397T mutations cause borderline mild/moderate disease. The origins of the G60S, R248Q, T296M, and I397T founders appear to be English/Dutch, Irish, German/Amish, and French, respectively. In addition to the predominant founder mutation, haplotype analysis reveals occasional independent mutations for G60S, R248Q and T296M which occur at a CpG dinucleotide (83) .
Putative founder effects at R248Q and T296M in MexicanHispanic patients with hemophilia B account for 19% of the observed mutations in the Mexican-Hispanic population (83). However, haplotype analysis demonstrates that the Mexican founders are different than those in the U.S. Caucasian population. In Turks, an independent T296M mutation accounts for one of two known mutations in patients with mild disease (84) . Thus, a significant number of the mutations causing mild or mildmoderate disease result from mutations at G60S, R248Q, and T296M. This conclusion is supported by previous populationbased studies of factor IX mutations which show that 37% of patients have mild disease (85) . Of these, approximately twothirds are due to founder effects in the U.S. Caucasian population (82) , suggesting that 13% of all independent disease causing mutations in the factor IX gene result in mild hemophilia B. Thus, the factor IX gene generally behaves like an 'on-off switch', i.e., most missense mutations will not cause any substantial loss of factor IX activity, while the majority of the remaining missense mutations will cause a near complete loss (>20-fold) of protein function. Mutations at very few sites produce mild disease in which there is a 4-fold to 20-fold loss of factor IX coagulant activity (85) . Since the small target size for mutations causing mild disease includes three CpG transitions, known hotspots for mutation, missense changes at these sites account for a significant fraction of all independent mutations.
V. MUTATION RATES
The mutations observed in patients with Mendelian diseases result from: the underlying pattern of mutation, the biology of the gene, the biology of the disease, and ascertainment biases. The underlying mutational pattern is often heavily distorted by the latter factors. The dystrophin gene illustrates the point. The 2.2 Mb gene is a huge target for deletions, larger than the complete genome of H. influenza. In addition, most of the dystrophin protein product is composed of repetitive domains. Most missense mutations do not cause disease and even deletions of multiple domains may cause only mild disease if the proper reading frame is maintained (86) . Thus, the enhancement of large deletions observed in most patients with Duchenne muscular dystrophy reflects the biology of the gene rather than the underlying pattern of mutation at that locus.
The rate of germline mutation per basepair per generation has been estimated by many different methods and these estimates vary from 2.5-90 × 10 -9 (1, 57, (87) (88) (89) (90) . The two most direct methods yielded estimates of 10 × 10 -9 (from electrophoretic variants of polypeptides) (88) and 8.6 × 10 -9 (from a meta-analysis of 40 cases worldwide of de novo mutations producing unstable hemoglobin or hemoglobin M) (89) . For the reasons outlined in Table 1 , the analysis of patients with hemophilia B has provided an ideal model for deducing the underlying pattern of germline mutation within the past 150 years [see (3) for details]. A compilation of the underlying mutation rates in the factor IX gene (Table 3) suggests that transitions and transversions at non-CpG dinucleotides occur 15-fold and 7-fold more frequently than microdeletions/microinsertions, respectively. Transitions and transversions at CpG dinucleotides are enhanced 17-fold and 5-fold relative to transitions and transversions at non-CpG dinucleotides, respectively. In combination, transitions and transversions should account for 96.1% of the types of de novo mutations amenable to analysis with this system. If the underlying mutation rates in the factor IX gene are typical of the genome, the aggregate mutation rate is about 3.6 × 10 -9 . (Ketterling et al., unpublished) . e Values were calculated for deletions of 200-200 000 bp as the likelihood that the junction of the deletion would occur at a given base (28) . The rate of deletions for the range 21-200 bp is unknown, but the mutation rate is unlikely to be greater than 0.256 × 10 -10 (p <0.05). f The overall mutation rate = total number of mutations divided by 6 × 10 9 bp. The total number of mutations is calculated by multiplying the mutation rate by the estimated target size for each type of mutation, multiplying by two to give the number of mutations per diploid individual, and summing the values.
When these mutation rates are extrapolated to the genome, each person should have about 21 de novo germline mutations [12.2 non-CpG and 2.8 CpG transitions, 5.3 non-CpG and 0.4 CpG transversions, 0.8 microdeletions/microinsertions, and 0.02 large deletions (>20 bp)]. Some of these de novo mutations are more likely to produce functional defects than others, i.e., while only 0.1% of all underlying mutations are deletions, deletions account for 5% of all observed mutations causing hemophilia B.
VI. THE FACTOR IX GENE AS A 'GERMLINE MUTAGEN TEST'
At least four lines of evidence suggest that endogenous processes are overwhelmingly the cause of germline mutations [reviewed in (3, 7) ]: (i) about 1/4 of all independent mutations causing hemophilia B are transitions at CpG (1,2,91) which arise secondary to spontaneous deamination of endogenously methylated cytosines; (ii) the germline mutational pattern found in all but one ethnic population (see below) is compatible with the postulated ancient mutational pattern that fashioned the G+C content of 40% and the nonrandom dinucleotide frequencies within the factor IX locus (92); (iii) the pattern of mutation observed in factor IX deficient patients has remained constant when compared with the evolutionary pattern deduced from direct sequence analysis of factor IX introns in primates (Grouse et al., manuscript in preparation); and (iv) the pattern of polymorphism in human factor IX intronic sequences and the pattern of sequence changes fixed during primate evolution are highly similar to the mutational pattern observed in patients with hemophilia B (Feng et al., manuscript in preparation) . With the exception of ubiquitous mutagens such as cosmic rays, the pattern of germline mutation in hemophiliacs should vary between populations if environmental mutagens predominated because: (i) different environments, diets, or lifestyles should lead to differential mutagen exposures, and (ii) mutagens tend to produce highly recognizable patterns or 'fingerprints' of mutation (93) . Extensive data on somatic mutations in the p53 gene illustrate the highly specific patterns of mutation that are produced by mutagens such as ultraviolet radiation, aflatoxin, and cigarette smoke (94) .
Deviation from the germline mutational pattern is expected if a population is exposed to physiologically important germline mutagens or if there are relevant genetic differences. Even small differences in the overall mutation rate can alter the pattern of mutation significantly. Thus, the factor IX gene can serve as a molecular epidemiological screen for the presence of a significant germline mutagen within a population. Previously, the pattern of germline mutation in the factor IX gene was found to be similar in a small Asian (mostly Korean) hemophilia B sample and a U.S. Caucasian sample of mostly Western European descent (95) . Subsequently, similar mutational patterns were observed in a larger study in which direct sequence analysis was coupled with haplotype analysis to determine recurrent, independent mutations from common 'founder' mutations, in the following hemophilia B populations: (i) 22 Asians; (ii) 22 U.S. minorities (Hispanics, Blacks, and AmerIndians); (iii) 24 patients whose mutations originated outside of the United States, Canada, and Europe; (iv) 127 Caucasians of Western European descent; and (v) 32 Mexican-Hispanics (83, 96) .
Recently, 36 independent sequence changes were defined in Chinese hemophilia B patients from the Peoples Republic of China (PRC) (Liu et al., submitted) . The pattern of mutation in the PRC Chinese population differs significantly from the pattern previously described in U.S. Caucasians (p = 0.01; Fisher exact test) (Table 4) . Similar results were obtained when the categories of mutation were divided further to examine each of the six types of transitions and transversions at non-CpG dinucleotides. Pairwise analysis for each mutation type indicates that, in comparison with the U.S. Caucasian hemophilia B sample, the PRC hemophilia B patients have fewer non-CpG transitions (p = 0.008 for this category of mutation versus all other mutations) and a moderate increase in microdeletions/microinsertions (p = 0.09 for this category versus all others). To control for the possibility that mild and moderate hemophilia B may be underrepresented in the PRC sample, the patterns of mutation were compared for families with severe hemophilia B ( Table 4) . Comparison of the 26 PRC patients and the 101 U.S. Caucasian patients with severe disease confirm that the observed patterns of mutation differ significantly (p = 0.01). These different mutational patterns may reflect genetic differences between the two populations. However, while the previously analyzed Asian population, (predominantly Korean) is genetically similar to the Chinese, the mutational pattern is similar to U.S. Caucasians (p = 0.73). In addition, Chinese patients from Taiwan and Hong Kong have an intermediate pattern which is not significantly different from the U.S. Caucasian or PRC patterns. While these data are intriguing, additional study is needed to distinguish between mutagen exposure, genetic differences and ascertainment biases/statistical artifact.
VII. DOES CANCER PROTECT THE INTEGRITY OF THE GENOME?
Since multiple lines of evidence support endogenous control of recent germline mutations in the factor IX gene at a level compatible with the ancient pattern that shaped the mammalian genome (see above), it has been speculated that an optimal germline mutation rate might exist in humans and other mammals at a level just sufficient to maintain adequate biological variation (97) . In brief, sexual reproduction and recombination enhance variation, but ultimately new germline mutation is required to replenish variant alleles that are lost by negative selection, genetic drift, and population bottlenecks. If selection maintains an optimal rate of mutation, cancer may be the most important mediator (98) . Early onset cancer can result if somatic cells are affected by germline mutations that generate high levels of mutagenic byproducts or compromise DNA repair or replication. The multiple mutations necessary for neoplasia serve to amplify any differences in the mutation rate, thereby providing an efficient selection against individuals that have even small increases in the rate of germline mutation. From this viewpoint, the similar fraction of humans, dogs, or outbred mice that develop early-onset cancer (99,100) (before the end of the female reproductive period) include individuals who: (i) experience the misfortune of developing early onset somatic mutations in the requisite tumor suppressor genes and oncogenes; (ii) inherit a germline defect in a tumor suppressor gene (or oncogene) such as individuals with familial retinoblastoma or Li-Fraumeni syndrome; or (iii) inherit germline defects in any of hundreds of genes that affect the rate of germline mutation. For the unfortunate individuals who inherit germline defects that could increase the rate of germline mutation, early onset cancer serves to guard the integrity of the genome and thereby the overall health of the species.
Hereditary nonpolyposis colorectal cancer (HNPCC), an autosomal dominant disease associated with colon and multiple other types of cancer, illustrates how 'mutator' mutations can be eliminated efficiently from the germline often before there is any increase in the rate of germline mutation. Patients with the disease carry a germline defect in one allele of MSH2, or another gene critical for mismatch repair (101) . While the somatic mutation rate in heterozygotes may not be detectably elevated, a spontaneous, deleterious somatic mutation in the second allele is associated with a dramatic increase in the rate of additional point mutations in other genes (102) . In addition, marked instability of microsatellite sequences also has been observed (103) . Germline mutations in the MSH2 gene are eliminated rapidly from the population within a few generations, because a substantial fraction of individuals with these mutations (∼30%) contract cancer between ages 10-40 (104) .
In conclusion, study of the factor IX gene continues to illuminate the germline mutational process. It will be important to assess locus-specific differences by performing similar detailed analyses in additional Mendelian diseases for which the underlying pattern of mutation can be inferred.
